EMA Authorised: Kirsty (previously Kixelle) (insulin aspart) — Biosimilar Collaborations Ireland Limited

View source ↗

Summary

EMA authorised Kirsty, a biosimilar insulin aspart product for diabetes mellitus, marketed by Biosimilar Collaborations Ireland Limited (previously named Kixell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Kirsty (insulin aspart)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus. MAH: Biosimilar Collaborations Ireland Limited. Decision date: 11/03/2026